Abstract
An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | British Journal of Haematology |
| Vol/bind | 193 |
| Udgave nummer | 6 |
| Sider (fra-til) | 1105-1109 |
| ISSN | 0007-1048 |
| DOI | |
| Status | Udgivet - jun. 2021 |
Bibliografisk note
Funding Information:The authors wish to thank all the patients and their families for their participation in this trial. The study was funded by Oncopeptides AB, Stockholm, Sweden; the manufacturer of melphalan flufenamide (melflufen). The authors would like to acknowledge Shala Thomas, PhD, of Team 9 Science for medical writing support funded by Oncopeptides AB, Stockholm, Sweden.
Funding Information:
Sara Bringhen has received honoraria from Bristol‐Myers Squibb, Celgene, Amgen, and Janssen and has been an advisor/consultant for Celgene, Amgen, Janssen, Takeda, and Karyopharm. Peter M. Voorhees has been an advisor/consultant for Adaptive Biotechnologies, Bristol‐Myers Squibb, Oncopeptides, Celgene, Novartis, Janssen, Takeda, and TeneoBio and has received research funding from Celgene, Janssen, Takeda, Amgen, and GlaxoSmithKline. Torben Plesner has been a consultant for Janssen, Celgene, AbbVie, Takeda, and Oncopeptides and has received research support from Janssen, Celgene, AbbVie, and Takeda. Ulf‐Henrik Mellqvist has received research funding from Oncopeptides, has been an advisor for Amgen, and has received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, Sandoz, and Oncopeptides. Brandi Reeves has received personal fees from Celgene, Takeda Oncology, Incyte, and Seattle Genetics. Pieter Sonneveld has received research support from Amgen, Celgene, Janssen, Takeda, and SkylineDx and is a consultant for Amgen, Celgene, Janssen, Oncopeptides, Takeda, and SkylineDx. Catriona Byrne is a consultant for and owns stock options in Oncopeptides and has been a consultant for Takeda, the Multiple Myeloma Research Consortium, and Dana‐Farber Cancer Institute. Eva Nordström and Jakob Obermüller are employees of and own stock and stock options in Oncopeptides. Johan Harmenberg is a consultant of and owns stock and stock options in Oncopeptides. Paul G. Richardson has been an advisor for Oncopeptides, Celgene, Takeda, Amgen, Janssen, and Karyopharm and has received grants from Bristol‐Myers Squibb, Oncopeptides, Celgene, and Takeda.
Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.